Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Mara D. Chambers, MD

| 4.84 out of 5
73 ratings | 16 comments
Mara D. Chambers, MD
Request an Appointment Physician Referral

Specialties

  • Breast Cancer Team
  • Medical Oncology
  • About

    Faculty Rank

    Associate Professor of Medicine

    Degree

    University of Louisville School of Medicine

    Residency

    University of Louisville School of Medicine

    Fellowship

    Medical Oncology and Hematology, University of Kentucky

    Certifications and Special Training

    American Board of Internal Medicine, Medical Oncology

  • Publications

    1. A Narrative Review of the Confluence of Breast Cancer and Low-wage Employment and Its Impact on Receipt of Guideline-recommended Treatment. Vanderpool RC, Swanberg JE, Chambers MD. Glob Adv Health Med. 2013 Sep;2(5):75-85.
    2. Iron deficiency anemia. Killip S, Bennett JM, Chambers MD. Am Fam Physician. 2007 Mar 1;75(5):671-8.
    3. Plasma TNF-α and soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study. Hayslip J, Dressler EV, Weiss H, Taylor TJ, Chambers M, Noel T, Miriyala S, Keeney JT, Ren X, Sultana R, Vore M, Butterfield DA, St. Clair D, Moscow JA. PLoS One 2015 Apr 24; 10 (4): e0124988.
    4. Impact of estrogen receptor (ER) and human epidermal growth factor receptor- 2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S. Breast Cancer Res Treat. 2014 Nov; 148 (2): 437-44 Abstracts/Presentations.
    5. Everolimus benefit in estrogen receptor (ER)-positive breast cancer is not linked to genomic alterations of the PI3K/AKT/mTOR pathway. Suleiman Massarweh, Edward Romond, Juliann Chmielecki, James Sun, Vera Kadamyan-Melkumyan, Mara Chambers, Rachel Stewart, Emily Van Meter Dressler, Murtaza Mehdi, Craig Horbinski, and Esther P Black. Stanford University and Cancer Institute, Stanford, CA 94304, University of Kentucky and Markey Cancer Center, Lexington, KY 40536, and Foundation Medicine, Cambridge, MA, United States
    6. Mutations in distinct components of the PI3K/AKT/mTOR pathway may define endocrine sensitivity in estrogen receptor (ER)-positive breast cancer. Esther P Black, Edward Romond, Juliann Chmielecki, James Sun, Rachel Stewart, Emily Van Meter Dressler, Vera Kadamyan-Melkumyan, Mara Chambers, Craig Horbinski, Murtaza Mehdi, and Suleiman Massarweh. Stanford University and Cancer Institute,
      Stanford, CA 94304, University of Kentucky and Markey Cancer Center, Lexington, KY 40536, and Foundation Medicine, Cambridge, MA, United States.
    7. A phase II study of combined fulvestrant and RAD001 (everolimus) in metastatic estrogen receptor (ER) positive breast cancer after aromatase inhibitor (A1) failure. Croley J, Black EP, Romond E, Chambers M, Waynick S, Slone S, Waynick C, Stevens M, Weiss H, and Massarweh S. Poster Presentation, San Antonio Breast Cancer Symposium, 2012.
    8. A phase II trial of fulvestrant and RAD001 (Everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; A study in progress. Badin F, Romond E, Chambers M, Shelton B, Birk S, Kadamyan V, Weiss H, and Massarweh S. Cancer Res 2010; 70(24 suppl): Abstract nr P4-02-05.
  • Research

    Cancer Center Member

    Programs

    • Drug Discovery, Delivery and Translational Therapeutics

    College & Department

    • College of Medicine
    • Department of Internal Medicine
  • Ratings & Reviews

    | 4.84 out of 5
    73 ratings |16 comments

    The star rating is a calculation based on feedback from our patients using our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more about our survey process. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    September, 2019
    *Dr. Chambers, as well as the rest of the staff at CBCC, is very efficient & skilled, as well as kind & caring.

    September, 2019
    Very appreciative of the time Dr Chambers spent with me and my husband discussing cancer concerns. Not only is she very patient but she listens carefully and is very thorough and clear. I have a low grade recurrent breast cancer but other health issues that were very concerning to me in terms of aromatase inhibitor therapy. She listened to those concerns, had reviewed my record and walked us through my options with both risks and benefits. This felt very collaborative and was definitely helpful to us. This was my first and only contact with her. I was extremely thankful for her caring and intelligent approach to my case.

    August, 2019
    Very professional, always a very positive experience.

    July, 2019
    they did an outstanding job of balancing my needs and my father having surgery.

    June, 2019
    I have not yet started treatment with my cancer, so far my surgery experience and my follow up care have been excellent. My initial experience to set up my chemo has been great

Are you happy with the care you received from this provider?

Please let us know by filling out a patient satisfaction survey when you get one. You can also leave an online review by clicking the button below.

Leave a review